Elsevier

Metabolism

Volume 42, Issue 7, July 1993, Pages 888-894
Metabolism

Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies

https://doi.org/10.1016/0026-0495(93)90065-VGet rights and content

Abstract

Familial hypercholesterolemia is a disorder of lipid metabolism associated with a highly increased risk for cardiovascular disease. Since in such patients even combined drug therapy often fails to decrease low-density lipoprotein (LDL) cholesterol levels sufficiently, extracorporeal LDL elimination has been developed. We treated eight adult patients with LDL immunoadsorption using antibodies against apolipoprotein B without additional lipid-lowering drug therapy for 3 years; this procedure was performed at weekly intervals. By one treatment session, LDL cholesterol and lipoprotein(a) levels were decreased by 55%. Under regular treatment, mean LDL cholesterol levels of 165 mg/dL between two consecutive treatment sessions could be reached, compared with 522 ± 24 mg/dL before any treatment. As high-density lipoprotein (HDL) cholesterol levels increased under regular treatment, the LDLHDL cholesterol ratio decreased from 13.4 to 3.4. Positive influences on plasma and whole-blood viscosity as well as on erythrocyte aggregation also seem to be beneficial with regard to retarding atherosclerosis. Very-low-density lipoprotein (VLDL) levels were reduced by approximately 50% after treatment, accompanied by a marked increase of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activity. The effects of LDL apheresis on hemostasis, complement activation transport proteins, and hematological parameters were found to be small. In addition, no side effects amounting to any major clinical relevance occurred in any of the patients. After 3 years of LDL apheresis, a decrease in the frequency of anginal chest pain and ST segment depression on exercise testing and a marked reduction of tendon xanthoma size were observed.

References (37)

  • ME King et al.

    Plasma-exchange therapy of homozygous familial hypercholesterolemia

    N Engl J Med

    (1980)
  • V Hombach et al.

    Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-Apherese

    Dtsch Med Wochenschr

    (1986)
  • H Borberg et al.

    Treatment of familial hypercholesterolemia by means of specific immunoadsorption

    J Clin Apheresis

    (1988)
  • S Yokoyama et al.

    Selective removal of low density lipoproteins by plasmapheresis in familial hypercholesterolemia

    Arteriosclerosis

    (1985)
  • T Eisenhauer et al.

    Selective removal of low density lipoproteins (LDL) by precipitation at low pH: First clinical application of the HELP system

    Klin Wochenschr

    (1987)
  • D Seidel et al.

    The HELP-LDL-Apheresis Multicentre Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months

    Eur J Clin Invest

    (1991)
  • H von Baeyer et al.

    Die Behandlung der familiären Hypercholesterinämie Typ IIa mit Membran-LDL-Apherese. Technik und Langzeit-Ergebnisse

    Nieren Hochdruckkrankheiten

    (1987)
  • T Nagasaki et al.

    A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity

    Clin Chim Acta

    (1977)
  • Cited by (92)

    • Simple emulsion template method towards self-anticoagulant and high-efficiency carboxymethyl chitosan-based adsorbent for low-density lipoprotein from whole blood

      2023, Journal of Colloid and Interface Science
      Citation Excerpt :

      Most relevant researches have focused on modifying the functional groups on substrates of adsorbents. According to adsorption principles and ligands, the currently available LDL adsorbents can be divided into immunosorbent [10], anionic sorbent [11,12], hydrophobic sorbent [13] and amphiphilic sorbent [14]. As a research hotspot and frontier trend, anionic adsorbents can selectively bind the positively charged apolipoprotein B100 by their negatively charged groups [15].

    • Lipoprotein Apheresis

      2016, Endocrinology and Metabolism Clinics of North America
    • Lipoprotein Apheresis

      2015, Cardiology Clinics
      Citation Excerpt :

      The mechanism by which LA acutely lowers HDL-C (10%–20%) is not fully understood because, unlike apoB lipoproteins, the HDL-C is negative charged. Some explanations involve filtration, hemodilution, activation of hepatic triglyceride lipase (HTGL), or the decreased activity of lecithin-cholesterol acyltransferase.29 Several studies30,31 of LA therapy have revealed a greater acute reduction of total HDL than apolipoprotein A-I, the primary HDL lipoprotein involved in reverse cholesterol transport, and that most of the HDL-C removed following LA is a proinflammatory type, as measured by the inability of HDL to inhibit LDL-induced monocyte chemotactic activity.32,33

    • Current situation of lipoprotein apheresis in Saxony

      2013, Atherosclerosis Supplements
      Citation Excerpt :

      Additionally, it compares the efficiency of the LA treatment at the UHD with that at other centers. Six lipoprotein apheresis methods were used, for details about these methods see the literature [4–10] (Table 1). In 2010, 119 patients were treated with lipoprotein apheresis in Saxony (Table 2), more than half of them at the UHD Apheresis Center.

    View all citing articles on Scopus

    Supported by a grant from the Bundesminister für Forschung und Technologie (BMFT 01ZJ85014).

    View full text